Enzo Biochem, Inc. ($0.01 Par Value) (ENZ) News
Filter ENZ News Items
ENZ News Results
|Loading, please wait...|
Latest ENZ News From Around the Web
Below are the latest news stories about Enzo Biochem Inc that investors may wish to consider to help them evaluate ENZ as an investment opportunity.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Enzo Biochem (ENZ) announced that on Jan. 21 the company served a notice of termination to former CEO Elazar Rabbani regarding his employment
Investment company Evermore Global Advisors, LLC (Current Portfolio) buys Eneti Inc, sells Enzo Biochem Inc, Calumet Specialty Products Partners LP, Vimeo Inc, Constellium SE during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Evermore Global Advisors, LLC.
Investment company Corrado Advisors, Llc (Current Portfolio) buys Innovator Emerging Markets Power Buffer ETF - Octo, Innovator International Developed Power Buffer ETF, iShares Core S&P Total U.S.
NEW YORK, NY, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics company, today announced the appointments of Hamid Erfanian and Bradley Radoff to the Company’s Board of Directors (the “Board”), effective immediately. The Company also announced that directors Dov Perlysky and Rebecca Fischer will step down from the Board immediately to facilitate a smooth transition for the new Board members. Dr. Mary Tagliaferri will
Genetron (NASDAQ:GTH) and Enzo Biochem (NYSE:ENZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings. Profitability This table compares Genetron and Enzo Biochems net margins, return on equity and return on 
No summary available.
Conference call and live webcast scheduled for today, Wednesday, December 15, 2021 at 4:30 pm (ET)
1Q FY 2022 revenues of $26.5 million vs. $24.8 million in 4Q FY 2021, representing a 7% sequential increaseCompany appoints Hamid Erfanian as Chief Executive Officer Consolidated manufacturing footprint at state-of-the-art Farmingdale, NY campus to enhance operational efficiencies Conference call and live webcast scheduled for today,Wednesday, December 15, 2021 at 4:30 pm (ET) NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company
Millennium Management LLC grew its position in shares of Enzo Biochem, Inc. (NYSE:ENZ) by 324.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 414,682 shares of the medical research companys stock after purchasing an additional 316,940 shares during the period. Millennium